KA

KINETA INC
NASDAQ
7.98
+0.15
+1.92%
Opening 11:19 01/27 EST
OPEN
8.22
PREV CLOSE
7.83
HIGH
8.22
LOW
7.95
VOLUME
4.30K
TURNOVER
24.90K
52 WEEK HIGH
9.00
52 WEEK LOW
1.619
MARKET CAP
11.17M
P/E (TTM)
-2.6595
1D
5D
1M
3M
1Y
5Y
3 Stocks Insiders Are Buying: Lovesac And More
Benzinga · 01/05 12:02
BRIEF-Kineta Receives Notice Of Termination Of Exclusive Option,License Agreement From Genentech
Reuters · 12/30/2022 22:08
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/30/2022 17:28
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 12/21/2022 18:51
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 12/21/2022 17:32
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/20/2022 13:07
UPDATE: Kineta's Shares Gain Momentum on Nasdaq Debut Following Yumanity Therapeutics Reverse Merger Completion
UPDATE: Kineta's Shares Gain Momentum on Nasdaq Debut Following Yumanity Therapeutics Reverse Merger Completion
MT Newswires · 12/19/2022 11:07
Kineta, Yumanity Therapeutics Complete Reverse Merger
Kineta, Yumanity Therapeutics Complete Reverse Merger
MT Newswires · 12/19/2022 07:48
More
About KA
Kineta, Inc., formerly Yumanity Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The Company's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.

Webull offers kinds of Kineta Inc stock information, including NASDAQ:KA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KA stock methods without spending real money on the virtual paper trading platform.